Alvotech Lux Holdings S.A.S.
ALVO | $13.39 0.45% 0.45% 200K
|
n/a
(0.0% 1d) (0.5% 1m) (48.3% 1y) (0.0% 2d) (0.0% 3d) (3.3% 7d) (-89.04% volume)
Earnings Calendar:
Market Cap: $ 3,572,744,491
Sec Filling | Patents | 917 employees
alvotech was founded in 2013, with the clear mission to become a global leader in biogenerics, defined as differentiated, high-quality, cost-controlled biosimilars. we have pursued this goal by creating a fully-integrated specialty company in control of every value adding development step from cell line development to commercial manufacturing of the product. our in-house development and manufacturing platform located at four sites across europe drives timely development of a strong and differentiated portfolio, while our state-of-the-art flexible manufacturing facility, located in reykjavik iceland, ensures high quality and cost-effective production. we are passionate about what we have created and our stated purpose of transforming access to life-altering therapies for patients across the globe. we believe in focus and specialization and each of our 250 professionals share our passion and pride to be part of this mission. we are dedicated to making people's lives better by improving a
t-cell
add to watch list Paper trade email alert is off
Press-releases
Alvotech signs U.S. agreement to expand access for newly approved high-concentration interchangeable biosimilar to Humira® (adalimumab)
Published: 2024-04-19 (Crawled : 10:00) - globenewswire.com
ALVO | $13.39 0.45% 0.45% 200K
|
n/a
|
| O: 1.16%
H: 7.28%
C: 1.3%
KMDA | $5.1 -0.99% 5.3K
|
Health Technology
|
| O: 1.76%
H: 0.0%
C: 0.0%
humira biosimilar approved for agreement
Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)
Published: 2024-04-16 (Crawled : 21:00) - globenewswire.com
JNJ | News | $149.56 0.3% 0.0% 9.1M
|
Health Technology
|
| O: -0.04%
H: 0.28%
C: -0.16%
stelara fda biosimilar approval teva
Alvotech Hosts Audio Call for Investors at 8:15 am EDT on April 3, 2024
Published: 2024-04-03 (Crawled : 11:00) - globenewswire.com
ALVO | $13.39 0.45% 0.45% 200K
|
n/a
|
| O: 2.98%
H: 0.17%
C: -0.43%
KMDA | $5.1 -0.99% 5.3K
|
Health Technology
|
| O: -0.18%
H: 2.16%
C: 0.9%
audio
Alvotech Announces Increase in Number of Own Shares
Published: 2024-03-22 (Crawled : 20:00) - globenewswire.com
KMDA | $5.1 -0.99% 5.3K
|
Health Technology
| Email alert
Add to watchlist
TEVJF | News | $12.37 -24.22% 380
|
Health Technology
| Email alert
Add to watchlist
ALVO | $13.39 0.45% 0.45% 200K
|
n/a
| Email alert
Add to watchlist
Alvotech Reports Financial Results for Full Year 2023 and Provides a Business Update
Published: 2024-03-20 (Crawled : 20:00) - globenewswire.com
ALVO | $13.39 0.45% 0.45% 200K
|
n/a
|
| O: -1.58%
H: 1.87%
C: 0.53%
JNJ | News | $149.56 0.3% 0.0% 9.1M
|
Health Technology
|
| O: -0.03%
H: 0.0%
C: 0.0%
ABBV | News | $169.54 0.98% -0.91% 4.1M
|
Health Technology
|
| O: -0.89%
H: 0.0%
C: 0.0%
KMDA | $5.1 -0.99% 5.3K
|
Health Technology
|
| O: 0.68%
H: 0.0%
C: -1.86%
AMGN | News | $273.69 0.66% 0.65% 2.5M
|
Health Technology
|
| O: 0.58%
H: 1.2%
C: 0.84%
business year update financial results
Alvotech Announces Webcast of Full Year 2023 Financial Results on March 21, 2024, at 8:00 am ET
Published: 2024-03-05 (Crawled : 21:00) - globenewswire.com
ALVO | $13.39 0.45% 0.45% 200K
|
n/a
|
| O: -0.99%
H: 0.75%
C: -0.13%
KMDA | $5.1 -0.99% 5.3K
|
Health Technology
|
| O: -6.12%
H: 1.67%
C: 1.17%
year financial results
Alvotech Appoints Interim Chief Quality Officer
Published: 2024-02-29 (Crawled : 21:00) - globenewswire.com
ALVO | $13.39 0.45% 0.45% 200K
|
n/a
|
| O: -0.58%
H: 3.04%
C: 3.01%
KMDA | $5.1 -0.99% 5.3K
|
Health Technology
|
| O: -1.27%
H: 2.97%
C: 2.41%
Alvotech Accepts Offer for the Sale of Shares for a value of approximately USD 166 million at a Purchase price of USD 16.41 (ISK 2,250) per Share
Published: 2024-02-26 (Crawled : 10:00) - globenewswire.com
ALVO | $13.39 0.45% 0.45% 200K
|
n/a
|
| O: 11.35%
H: 0.84%
C: -3.25%
KMDA | $5.1 -0.99% 5.3K
|
Health Technology
|
| O: 0.0%
H: 1.6%
C: -0.49%
million
Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira®
Published: 2024-02-24 (Crawled : 04:20) - globenewswire.com
KMDA | $5.1 -0.99% 5.3K
|
Health Technology
| Email alert
Add to watchlist
TEVJF | News | $12.37 -24.22% 380
|
Health Technology
| Email alert
Add to watchlist
ALVO | $13.39 0.45% 0.45% 200K
|
n/a
| Email alert
Add to watchlist
simlandi first biosimilar approval teva
Alvotech Announces Expected Global Market Entry Dates for AVT04 Biosimilar to Stelara® (ustekinumab)
Published: 2024-02-15 (Crawled : 12:00) - globenewswire.com
ALVO | $13.39 0.45% 0.45% 200K
|
n/a
|
| O: 0.32%
H: 2.98%
C: 0.32%
JNJ | News | $149.56 0.3% 0.0% 9.1M
|
Health Technology
|
| O: -0.19%
H: 1.6%
C: 1.24%
KMDA | $5.1 -0.99% 5.3K
|
Health Technology
|
| O: 1.66%
H: 1.96%
C: 0.49%
avt04 stelara biosimilar expected global market
Last 15 days Sec forms
| File Id | Form | Published Date | Transaction Date | Direction | Code | Amount Transacted | Owned Amount |
Your Today's Watch List
Sign in to create a watchlistGainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News 4 | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Last 48 Hours Insiders Buying
CTRN P 29000 | $22.25 0.14% 0.13% 100K
|
Retail Trade
|
22:00
CONN | $3.71 1.37% 1.35% 72K
|
Retail Trade
|
21:30
TGEN P 6000 | $0.6897 39.71% 2.3K
|
Utilities
|
18:30
CMTV P 700 | $15.74 17.43% 12K
|
Finance and Insurance
|
18:30
FNB | $13.63 2.17% 0.0% 2.5M
|
Finance
|
17:30
RMCF | $3.57 0.28% 2.8K
|
Consumer Non-Durables
|
20:10